Irritable Bowel Syndrome Market Pipeline Review for H1 2015

Jul 27, 2015, 06:30 ET from ReportsnReports

DALLAS, July 27, 2015 /PRNewswire/ --

ReportsnReports.com adds Irritable Bowel Syndrome - Pipeline Review H1 2015 market research report on the IBS therapeutic development pipeline to the pharmaceuticals section of its online research reports library.

Complete report on Irritable Bowel Syndrome market pipeline spread across 123 pages, talking about 22 companies, 28 drug profiles and supported with 44 tables and 19 figures is now available at http://www.reportsnreports.com/reports/404735-irritable-bowel-syndrome-pipeline-review-h1-2015.html .

The Irritable Bowel Syndrome - Pipeline Review, H1 2015 market research report provides comprehensive information on the therapeutic development for IBS, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.

A. Menarini Industrie Farmaceutiche Riunite Srl, Actavis Plc, Alba Therapeutics Corporation, Alfa Wassermann S.p.A, Ardelyx, Inc., Astellas Pharma Inc., Dong-A Socio Group, GIcare Pharma Inc, Hanmi Pharmaceuticals, Co. Ltd., ImmusanT, Inc., Ironwood Pharmaceuticals, Inc., Juno Therapeutics Inc., Ono Pharmaceutical Co., Ltd., Protagonist Therapeutics Inc., RaQualia Pharma Inc., SK Biopharmaceuticals Co., Ltd., SK Chemicals Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Synergy Pharmaceuticals, Inc., Synthetic Biologics, Inc., Takeda Pharmaceutical Company Limited and Yuhan Corporation are the companies involved in Irritable Bowel Syndrome therapeutics development discussed in this H1 2015 research report.

The drug profiles covered include data and information on (Bacillus subtilis + mosapride + Streptococcus faecium), ASP-1017, ASP-7147, Blautix, DA-6886, DSP-6952, eluxadoline, GIC-1001, ibodutant, larazotide acetate, linaclotide, Monoclonal Antibody to Antagonize M3 for Irritable Bowel Syndrome, Nexvax-2, ONO-2952, plecanatide, relenopride hydrochloride, rifaximin, RQ-00202730, RQ-00310941, SKI-3246, Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine, Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD, SYN-010, Synthetic Peptides for Gastrointestinal Disorders, Synthetic Peptides for Irritable Bowel Syndrome and Inflammatory Bowel Disease, TAK-480, tenapanor hydrochloride and YH-12852. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Order a copy of Irritable Bowel Syndrome - Pipeline Review, H1 2015 market research report at http://www.reportsnreports.com/purchase.aspx?name=404735 .

The Irritable Bowel Syndrome - Pipeline Review, H1 2015 market research report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome while reviewing key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The research reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects and summarizes all the dormant and discontinued pipeline projects.  A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages and a detailed assessment of monotherapy and combination therapy pipeline projects are also covered. Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are included.

For the pharmaceuticals market and related topics, ReportsnReports.com has a range of newly published and relevant industry research reports from experts:

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023: Epidemiologists forecast that the total prevalent cases of IBS in the 7MM will increase from 40,777,607 total prevalent cases in 2013 to 42,366,389 by 2023, at a decadal growth rate of 3.9%. Specifically, Spain will have the highest growth in the total prevalent cases of IBS in the 7MM between 2013 and 2023, while Japan and Germany will have a decline in the total prevalent cases of IBS in the 7MM between 2013 and 2023. This analysis is supported by the use of epidemiological studies published in peer-reviewed journals and country-specific studies that provided the total prevalence of IBS using the Rome II diagnostic criteria. Epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of IBS; they segmented IBS by sex, age, and sub-classification of predominant bowel habits, which allows for a meaningful comparison of the disease populations between markets. The Irritable Bowel Syndrome (IBS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS segmented by sex, age (10-18 years, 19-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, and =85 years), and sub-classification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and un-subtyped IBS [IBS-U] in these markets. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. Spread across 49 pages and supported with  10 tables and 5 figures, this IBS epidemiology research report is available at http://www.reportsnreports.com/reports/313511-epicast-report-irritable-bowel-syndrome-epidemiology-forecast-to-2023.html .

About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest: www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@reportsandreports.com  


SOURCE ReportsnReports